Alnylam Pharmaceuticals

Vir Biotechnology will present Week 48 endpoint results from the Phase 2 SOLSTICE trial evaluating tobevibart alone or in combination with elebsiran for chronic hepatitis delta at AASLD 2025.

Ultragenyx Pharmaceutical appointed Eric Olson as Chief Business Officer and Executive Vice President effective September 22, 2025, following Thomas Kassberg's planned retirement after 14 years with the company.

Over 20 pharmaceutical and biotech companies are actively developing more than 20 therapeutic candidates for Huntington's disease at various clinical and preclinical stages.

Moderna has settled patent infringement lawsuits filed by Alnylam Pharmaceuticals over alleged misuse of lipid nanoparticle technology in COVID-19 vaccines.

Alnylam Pharmaceuticals has joined the Alliance for Genomic Discovery as the ninth member, gaining access to a comprehensive clinical genomic database containing 250,000 whole-genomes to accelerate RNA interference therapeutic development.

Biotech leaders John Maraganore and Clive Meanwell have launched Corsera Health with the ambitious goal of creating a world without cardiovascular disease.

Zilebesiran, developed by Alnylam Pharmaceuticals and Roche, targets angiotensinogen in the renin-angiotensin-aldosterone system and offers biannual dosing for hypertension management.

The U.S. District Court for the District of Delaware entered a final judgment on July 30, 2025, ruling that Pfizer's COVID-19 vaccine did not infringe any of Alnylam's patents covering nanoparticle technology.

The FDA has approved an updated label for Novartis' Leqvio (inclisiran) allowing its use as monotherapy alongside diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia.

The U.S. Court of Appeals for the Federal Circuit affirmed a district court ruling in favor of Moderna, rejecting Alnylam Pharmaceuticals' patent infringement claims over mRNA-based COVID-19 vaccine technology.